| For: | Xu JY, Li ZP, Zhang L, Ji G. Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(37): 13493-13500 [PMID: 25309079 DOI: 10.3748/wjg.v20.i37.13493] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i37/13493.htm |
| Number | Citing Articles |
| 1 |
Jingling Jin, Leila Valanejad, Thuy Phuong Nguyen, Kyle Lewis, Mary Wright, Ashley Cast, Lauren Stock, Lubov Timchenko, Nikolai A. Timchenko. Activation of CDK4 Triggers Development of Non-alcoholic Fatty Liver Disease. Cell Reports 2016; 16(3) doi: 10.1016/j.celrep.2016.06.019
|
| 2 |
George S Zacharia, Muhammad H Ashraf, Franklin Sosa, Anu Jacob, Harish Patel. Quick glance at 'metabolic dysfunction associated steatotic liver disease' therapeutics: Targets, trials, and trends. World Journal of Gastrointestinal Pharmacology and Therapeutics 2025; 16(4): 110827 doi: 10.4292/wjgpt.v16.i4.110827
|
| 3 |
Feifei Li, Qiujing Chen, Yang Dai, Lin Lu. Nuclear receptors as therapeutic targets in metabolic and cardiovascular disorders. iScience 2025; 28(12) doi: 10.1016/j.isci.2025.114042
|
| 4 |
Alexander Ravikumar, Sarvesh Sabarathinam. Guggulsterone as a modulator of the microbiota–bile acid–FXR axis: Molecular mechanisms and therapeutic potential in metabolic ageing. Biochimie 2026; doi: 10.1016/j.biochi.2026.06.001
|
| 5 |
Valéria Sutti Nunes, Guilherme da Silva Ferreira, Eder Carlos Rocha Quintão. Cholesterol metabolism in aging simultaneously altered in liver and nervous system. Aging 2022; 14(3) doi: 10.18632/aging.203880
|
| 6 |
Kyeongjin Kim, Kook Hwan Kim. Targeting of Secretory Proteins as a Therapeutic Strategy for Treatment of Nonalcoholic Steatohepatitis (NASH). International Journal of Molecular Sciences 2020; 21(7) doi: 10.3390/ijms21072296
|
| 7 |
朝安 郑. Pathogenesis of Nonalcoholic Fatty Liver Disease in Children and Adolescents. Advances in Clinical Medicine 2020; 10(03) doi: 10.12677/ACM.2020.103057
|
| 8 |
Laura Inés Elvira-Torales, Inmaculada Navarro-González, Rocío González-Barrio, Gala Martín-Pozuelo, Guillermo Doménech, Juan Seva, Javier García-Alonso, María Jesús Periago-Castón. Tomato Juice Supplementation Influences the Gene Expression Related to Steatosis in Rats. Nutrients 2018; 10(9) doi: 10.3390/nu10091215
|
| 9 |
Jamal Nasser Saleh Al-maamari, Mahardian Rahmadi, Sisca Melani Panggono, Devita Ardina Prameswari, Eka Dewi Pratiwi, Chrismawan Ardianto, Santhra Segaran Balan, Budi Suprapti. The effects of quercetin on the expression of SREBP-1c mRNA in high-fat diet-induced NAFLD in mice. Journal of Basic and Clinical Physiology and Pharmacology 2021; 32(4) doi: 10.1515/jbcpp-2020-0423
|
| 10 |
Ayan Saha, Emily Wood, Luna Omeragic, Maya Minkara, Kethain Marma, Shipan Das Gupta, Jannatul Ferdoush. Farnesoid X Receptor (FXR) Agonists and Protein Kinase Regulation in NAFLD and NASH: Mechanisms and Therapeutic Potential. Kinases and Phosphatases 2025; 3(3) doi: 10.3390/kinasesphosphatases3030016
|
| 11 |
Graciela Arguello, Elisa Balboa, Marco Arrese, Silvana Zanlungo. Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2015; 1852(9) doi: 10.1016/j.bbadis.2015.05.015
|
| 12 |
Aliabbas Zia, Faezeh Sahebdel, Tahereh Farkhondeh, Milad Ashrafizadeh, Ali Zarrabi, Kiavash Hushmandi, Saeed Samarghandian. A review study on the modulation of SIRT1 expression by miRNAs in aging and age-associated diseases. International Journal of Biological Macromolecules 2021; 188 doi: 10.1016/j.ijbiomac.2021.08.013
|
| 13 |
Andrea Ferrigno, Laura Giuseppina Di Pasqua, Clarissa Berardo, Veronica Siciliano, Vittoria Rizzo, Luciano Adorini, Plinio Richelmi, Mariapia Vairetti, Gianfranco D. Alpini. The farnesoid X receptor agonist obeticholic acid upregulates biliary excretion of asymmetric dimethylarginine via MATE-1 during hepatic ischemia/reperfusion injury. PLOS ONE 2018; 13(1) doi: 10.1371/journal.pone.0191430
|
| 14 |
Gabriela S. de Castro, Philip C. Calder. Non-alcoholic fatty liver disease and its treatment with n-3 polyunsaturated fatty acids. Clinical Nutrition 2018; 37(1) doi: 10.1016/j.clnu.2017.01.006
|
| 15 |
Kazuya Okushin, Takeya Tsutsumi, Kenichiro Enooku, Hidetaka Fujinaga, Akira Kado, Junji Shibahara, Masashi Fukayama, Kyoji Moriya, Hiroshi Yotsuyanagi, Kazuhiko Koike. The intrahepatic expression levels of bile acid transporters are inversely correlated with the histological progression of nonalcoholic fatty liver disease. Journal of Gastroenterology 2016; 51(8) doi: 10.1007/s00535-015-1148-y
|
| 16 |
M.-Y. Park, S.J. Kim, E.K. Ko, S.-H. Ahn, H. Seo, M.-K. Sung. Gut microbiota-associated bile acid deconjugation accelerates hepatic steatosis in ob/ob mice. Journal of Applied Microbiology 2016; 121(3) doi: 10.1111/jam.13158
|
| 17 |
Nishika Sahini, Jürgen Borlak. Genomics of human fatty liver disease reveal mechanistically linked lipid droplet–associated gene regulations in bland steatosis and nonalcoholic steatohepatitis. Translational Research 2016; 177 doi: 10.1016/j.trsl.2016.06.003
|
| 18 |
Stanislav Nikolaevich Kotlyarov. Liver immunology: Biological role and clinical significance. World Journal of Hepatology 2025; 17(7): 107541 doi: 10.4254/wjh.v17.i7.107541
|
| 19 |
Matthew C. Cave, Heather B. Clair, Josiah E. Hardesty, K. Cameron Falkner, Wenke Feng, Barbara J. Clark, Jennifer Sidey, Hongxue Shi, Bashar A. Aqel, Craig J. McClain, Russell A. Prough. Nuclear receptors and nonalcoholic fatty liver disease. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms 2016; 1859(9) doi: 10.1016/j.bbagrm.2016.03.002
|
| 20 |
Sarah J. Glastras, Muh Geot Wong, Hui Chen, Jie Zhang, Amgad Zaky, Carol A. Pollock, Sonia Saad. FXR expression is associated with dysregulated glucose and lipid levels in the offspring kidney induced by maternal obesity. Nutrition & Metabolism 2015; 12(1) doi: 10.1186/s12986-015-0032-3
|
| 21 |
Yu-Yuan Li, Chuang-Yu Cao, You-lian Zhou, Yu-Qiang Nie, Jie Cao, Yong-Jian Zhou. The roles and interaction of FXR and PPARs in the pathogenesis of nonalcoholic fatty liver disease. Arab Journal of Gastroenterology 2020; 21(3) doi: 10.1016/j.ajg.2020.04.018
|
| 22 |
Nicholas W.S. Chew, Mark D. Muthiah, Arun J. Sanyal. Cardiovascular Endocrinology and Metabolism. 2023; doi: 10.1016/B978-0-323-99991-5.00003-6
|
| 23 |
Jingyi Guo, Shangyi Huang, Qincheng Yi, Naihua Liu, Tianqi Cui, Siwei Duan, Jiabing Chen, Jiayu Li, Jun Li, Lei Wang, Yong Gao, Guangning Nie. Hepatic Clstn3 Ameliorates Lipid Metabolism Disorders in High Fat Diet-Induced NAFLD through Activation of FXR. ACS Omega 2023; 8(29) doi: 10.1021/acsomega.3c02347
|
| 24 |
Giovanni Targher, Amedeo Lonardo, Christopher D. Byrne. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nature Reviews Endocrinology 2018; 14(2) doi: 10.1038/nrendo.2017.173
|
| 25 |
Michał Porada, Łukasz Bułdak. From Pathophysiology to Practice: Evolving Pharmacological Therapies, Clinical Complications, and Pharmacogenetic Considerations in Portal Hypertension. Metabolites 2025; 15(2) doi: 10.3390/metabo15020072
|
| 26 |
Chuan Ding, Zeping Wang, Xinyue Dou, Qiao Yang, Yan Ning, Shi Kao, Xianan Sang, Min Hao, Kuilong Wang, Mengyun Peng, Shuosheng Zhang, Xin Han, Gang Cao. Farnesoid X receptor: From Structure to Function and Its Pharmacology in Liver Fibrosis. Aging and disease 2023; doi: 10.14336/AD.2023.0830
|
| 27 |
Christine Marotta, Alaa Ahmad, Ed Luo, Jart Oosterhaven, Sjoerd van Marle, Nathalie Adda. EDP‐297: A novel, farnesoid X receptor agonist—Results of a phase I study in healthy subjects. Clinical and Translational Science 2023; 16(2) doi: 10.1111/cts.13453
|
| 28 |
David Tornai, Gyongyi Szabo. Emerging medical therapies for severe alcoholic hepatitis. Clinical and Molecular Hepatology 2020; 26(4) doi: 10.3350/cmh.2020.0145
|
| 29 |
Gabriela Moreira Soares, Kathia Regina Cantelli, Sandra Lucinei Balbo, Rosane Aparecida Ribeiro, Ana Claudia Paiva Alegre-Maller, Helena Cristina Barbosa-Sampaio, Antonio Carlos Boschero, Allan Cezar Faria Araújo, Maria Lúcia Bonfleur. Liver steatosis in hypothalamic obese rats improves after duodeno-jejunal bypass by reduction in de novo lipogenesis pathway. Life Sciences 2017; 188 doi: 10.1016/j.lfs.2017.08.035
|
| 30 |
Pietro Vajro, Marco Poeta, Claudia Mandato, Maria Grazia Clemente. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions. World Journal of Gastroenterology 2016; 22(36): 8078-8093 doi: 10.3748/wjg.v22.i36.8078
|
| 31 |
Qin Liu, Chun-Yan Niu. From “two hit theory” to “multiple hit theory”: Implications of evolution of pathogenesis concepts for treatment of non-alcoholic fatty liver disease. World Chinese Journal of Digestology 2019; 27(19) doi: 10.11569/wcjd.v27.i19.1171
|
| 32 |
Depeng Dai, Yuanhu Pan, CuiPing Zeng, Shenghui Liu, Yi Yan, Xiaoxiong Wu, Zaiyan Xu, Lisheng Zhang. Activated FXR promotes xenobiotic metabolism of T-2 toxin and attenuates oxidative stress in broiler chicken liver. Chemico-Biological Interactions 2020; 316 doi: 10.1016/j.cbi.2019.108912
|
| 33 |
|
| 34 |
Ayooluwatomiwa Deborah Adekunle, Adeyinka Adejumo, Ashwani K. Singal. Therapeutic targets in alcohol-associated liver disease: progress and challenges. Therapeutic Advances in Gastroenterology 2023; 16 doi: 10.1177/17562848231170946
|
| 35 |
Huan Nie, Yuanjun Deng, Chuiyang Zheng, Maoxing Pan, Jiqian Xie, Yupei Zhang, Qinhe Yang. A network pharmacology‐based approach to explore the effects of Chaihu Shugan powder on a non‐alcoholic fatty liver rat model through nuclear receptors. Journal of Cellular and Molecular Medicine 2020; 24(9) doi: 10.1111/jcmm.15166
|
| 36 |
Yu Yang, Yu Zhao, Wenzhen Li, Yuyao Wu, Xin Wang, Yijie Wang, Tingmei Liu, Tinghong Ye, Yongmei Xie, Zhiqiang Cheng, Jun He, Peng Bai, Yiwen Zhang, Liang Ouyang. Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment. European Journal of Medicinal Chemistry 2020; 197 doi: 10.1016/j.ejmech.2020.112311
|